Adora2A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ADORA2A (Adenosine A2a Receptor) encodes the adenosine A2a receptor, a Gs protein-coupled receptor that stimulates adenylate cyclase and increases intracellular cAMP levels. The ADORA2A gene is located on chromosome 22q11.23 and encodes a 412-amino acid protein primarily expressed in the striatum, olfactory tubercle, and other brain regions. This receptor is a major therapeutic target for Parkinson's disease, as A2a receptor antagonists (like istradefylline) reduce motor symptoms without the dyskinesias caused by dopaminergic drugs. Beyond movement disorders, ADORA2A is implicated in epilepsy, schizophrenia, sleep disorders, and neurodegenerative diseases.
The ADORA2A gene spans approximately 27 kb and consists of multiple exons. The gene exhibits:
| Polymorphism | Location | Functional Effect |
|---|---|---|
| 1976C>T | 3' UTR | Altered mRNA stability |
| -1325G>A | Promoter | Changed transcription factor binding |
| 1083C>T | Coding | Synonymous variant |
| 2592C>Tins | 3' UTR | microRNA binding site |
The adenosine A2a receptor is a typical GPCR with seven transmembrane domains:
Upon adenosine binding, A2a receptor activates Gs/olf proteins:
Adenosine → A2aR → Gs activation → Adenylyl cyclase ↑ → cAMP ↑ → PKA activation
↓
CREB phosphorylation
↓
Gene transcription changes
ADORA2A shows highly region-specific expression:
| Brain Region | Expression Level | Functional Role |
|---|---|---|
| Striatum (caudate/putamen) | Very High | Motor control, reward |
| Olfactory Tubercle | High | Olfactory processing |
| Nucleus Accumbens | High | Reward, motivation |
| Globus Pallidus | Moderate | Motor circuits |
| Thalamus | Moderate | Sensory integration |
| Cortex | Low-Moderate | Cognitive functions |
Peripherally, A2a receptors are expressed in:
In the striatum, A2a receptors are predominantly expressed in indirect pathway medium spiny neurons (MSNs) that co-express dopamine D2 receptors (D2R). This creates a unique GPCR interaction:
This interaction is the basis for A2a antagonist therapy in PD.
A2a receptor activation exerts both protective and damaging effects:
Protective effects:
Detrimental effects:
ADORA2A is central to PD therapy:
Clinical trials have demonstrated:
A2a receptors modulate seizure activity:
Evidence links A2a receptors to schizophrenia:
A2a receptor involvement in AD:
| Drug | Mechanism | Approval Status |
|---|---|---|
| Istradefylline | A2a antagonist | FDA approved (PD) |
| Preladenant | A2a antagonist | Phase III completed |
| Tozadenant | A2a antagonist | Phase III completed |
| KW-6002 | A2a antagonist | Approved in Japan |
The study of Adora2A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1]: https://pubmed.ncbi.nlm.nih.gov/10629201/ PMID:10629201
[2]: https://pubmed.ncbi.nlm.nih.gov/10816402/ PMID:10816402
[3]: https://pubmed.ncbi.nlm.nih.gov/15604288/ PMID:15604288
[4]: https://pubmed.ncbi.nlm.nih.gov/17585956/ PMID:17585956
[5]: https://pubmed.ncbi.nlm.nih.gov/19029120/ PMID:19029120
[6]: https://pubmed.ncbi.nlm.nih.gov/22815556/ PMID:22815556
[7]: https://pubmed.ncbi.nlm.nih.gov/26297750/ PMID:26297750
[8]: https://pubmed.ncbi.nlm.nih.gov/28645618/ PMID:28645618